The University of Florida is seeking a company interested in commercializing a closedloop neuroprosthetic microstimulation device for treating epileptic seizures. Epilepsy is the third most common neurologic disorder, affecting nearly 2.7 million Americans and causing 200,000 new cases every year. Annual healthcare and workplace-related costs due to epilepsy total nearly $12.5 billion, which makes it one of the most costly neurologic diseases. Because the incidence of epilepsy increases as people age, the U.S. population will see more cases of epilepsy due to the rapidly expanding number of elderly Americans. Currently, anti-epileptic drugs are the standard therapy for epilepsy. However, these drugs cause side effects. Additionally, about one-third of all patientsremain unresponsive to currently available medications. To overcome these drawbacks, University of Florida researchers have created a novel neuroprosthetic device that interacts with the brain to identify abnormal brain electrical activity and deliver timed specific levels of therapeutic stimulation that treat epileptic seizures before they occur.
ApplicationsPreventing and treating epileptic seizures
- Responds to individual abnormal neurons rather than global markers of seizure, which increases performance
- Provides patient-specific treatment that is unavailable in current therapies, which supplies a competitive advantage
- Proactively treats epilepsy and similar disorders that affect millions, which increases efficiency